The Limited Times

Now you can see non-English news...

Covid-19: BioNTech / Pfizer wants to increase production of its vaccine up to 2.5 billion doses

2021-03-30T12:16:25.479Z


The German laboratory BioNTech announced on Tuesday that it intended to manufacture in 2021 up to 2.5 billion doses of its developed vaccine


Big boost.

The German laboratory BioNTech announced on Tuesday that it intended to greatly increase the production capacities of its vaccine developed with the American Pfizer due to "optimization of production processes", "the expansion of the production network" , as well as the authorization to draw six doses from a vial, the company said in a statement.

She delivered with her partner, on March 23, "more than 200 million doses" in the world, explains the firm.

READ ALSO>

Vaccination against Covid-19: the delay of the EU could cost 123 billion euros in 2021

The approval last week of a new production site in Germany, in Marburg (south), should support the increase in these capacities with a production of 250 million doses expected in the first half, to eventually reach one billion doses per year.

The Marburg plant, around 100 kilometers from Frankfurt, is the second production center for the BioNTech / Pfizer vaccine in Europe, in addition to the Puurs plant in Belgium.

1.4 billion doses this year and an “increase in demand” to come

The vaccine, which was the first to be authorized in the United States and the European Union, is now administered in "more than 65 countries and regions", according to Ugur Sahin, boss and co-founder of the Mainz-based SME. (Where is).

"We are already seeing the first signs of a drop in Covid-19 cases and mortality in several countries," he explained, adding that the laboratory is now working on variants and additional clinical trials.

In particular, a study of the vaccine on children between 6 months and 12 years old was launched in March.

In total, BioNTech has orders for 1.4 billion doses this year and expects "increased demand," according to a statement.

The German-American alliance also has three production sites in the United States.

Recently, the European Medicines Agency (EMA) authorized the storage of this vaccine at freezer temperatures, higher than those so far allowed, which will facilitate its distribution.

VIDEO.

Here are the differences between the 4 vaccines that will be massively distributed in France

On the financial side, the vaccine against the Covid-19 allowed BioNTech to generate an annual profit of 15.2 million euros last year, against a loss of 179.2 million in 2019, according to the results published on Tuesday. .

The company expects total revenues of € 9.8 billion from signed delivery contracts, alongside increased investment in research and development in 2021. In total, BioNTech spent 645 million euros in research in 2020, up sharply due to the development of the coronavirus vaccine.

Source: leparis

All life articles on 2021-03-30

You may like

Trends 24h

Life/Entertain 2024-03-28T17:17:20.523Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.